EZH2 and central nervous system cancer: To further understand the prognostic ability of EZH2 in glioma, we evaluated the association of EZH2 expression with clinicopathologic variables and established a nomogram based on multivariate Cox regression analysis of the 1‐, 3‐ and 5‐year survival of glioma patients.